Patents by Inventor Mihalis Kariolis

Mihalis Kariolis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230062800
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 2, 2023
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON
  • Publication number: 20220220458
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: September 2, 2021
    Publication date: July 14, 2022
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Publication number: 20220184186
    Abstract: Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Dana ANDERSEN, Adam CATHERMAN, Tina GIESE, Gunasekaran KANNAN, Mihalis KARIOLIS, Cathal MAHON, Ankit PATEL
  • Publication number: 20220177576
    Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 9, 2022
    Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis Kariolis, Cathal Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
  • Patent number: 11136563
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 5, 2021
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, ARAVIVE BIOLOGICS, INC.
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Cynthia Fuh, Yu Miao, Susan Hershenson
  • Publication number: 20210198640
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: November 23, 2020
    Publication date: July 1, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Giuseppe Astarita, Mark S. Dennis, Jennifer A. Getz, Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman, Junhua Wang, Joy Yu Zuchero
  • Publication number: 20210130485
    Abstract: The present disclosure relates generally to Fc polypeptide dimers that contain a non-native transferrin receptor (TfR) binding site, do not substantially deplete reticulocytes in vivo, but retain binding to the Fc? receptor (Fc?R). The present disclosure also relates to an Fc polypeptide dimer that contains a non-native site that specifically binds TfR on one of the Fc polypeptides; a modification or modifications on the Fc polypeptide containing the TfR-binding site that reduces Fc?R binding when bound to TfR, where the other Fc polypeptide does not contain a TfR-binding site but retains Fc?R binding.
    Type: Application
    Filed: July 6, 2020
    Publication date: May 6, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Mihalis Kariolis, Wanda Kwan, Adam P. Silverman, Zachary K. Sweeney, Joy Yu Zuchero
  • Patent number: 10876176
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 29, 2020
    Assignees: Aravive Biologics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • Patent number: 10870837
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 22, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava
  • Publication number: 20200369746
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, Fc dimers and fusion proteins comprising such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: February 5, 2020
    Publication date: November 26, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20200317749
    Abstract: The present disclosure relates to albumin variants, derivatives and analogs thereof. In particular, provided are albumin variants that bind with increased efficiency to FcRn, including albumin variants that bind with increased efficiency at low pH levels but inefficiently or not at all at neutral pH levels. The albumin variants, derivatives, and analogs have an increased serum half-life when compared to naturally-occurring albumins.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 8, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Mark S. Dennis, Mihalis Kariolis, Adam Silverman
  • Publication number: 20200289627
    Abstract: Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.
    Type: Application
    Filed: February 5, 2020
    Publication date: September 17, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Mark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
  • Publication number: 20200277584
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 3, 2020
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Giuseppe ASTARITA, Mark S. DENNIS, Jennifer A. GETZ, Anastasia HENRY, Mihalis KARIOLIS, Cathal MAHON, Adam P. SILVERMAN, Ankita SRIVASTAVA, Julie ULLMAN, Junhua WANG, Joy Yu ZUCHERO
  • Publication number: 20200262890
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Application
    Filed: September 17, 2019
    Publication date: August 20, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Publication number: 20200223935
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Patent number: 10457717
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 29, 2019
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Publication number: 20190249155
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Application
    Filed: March 15, 2019
    Publication date: August 15, 2019
    Applicant: Denali Therapeutics Inc.
    Inventors: Anastasia Henry, Mihalis Kariolis, Cathal Mahon, Adam P. Silverman, Ankita Srivastava
  • Publication number: 20180237496
    Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 23, 2018
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
  • Publication number: 20180140679
    Abstract: Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6. The treatment may be combined with a cytoreductive therapy.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 24, 2018
    Inventors: Amato J. Giaccia, Jennifer R. Cochran, Yu Miao, Mihalis Kariolis
  • Publication number: 20180094034
    Abstract: Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Patrick O'Connor, Raymond Tabibiazar, Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao